Assembly BiosciencesASMB +3.93%31 Debt-to-Equity is 0.01 as of Mar. 2026, which is 75% below its 10-year median of 0.04. GuruFocus rates ASMB with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 965 Biotechnology companies, Assembly Biosciences ranks better than 99.9% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Assembly Biosciences's Debt-to-Equity or its related term are showing as below:
ASMB'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.04 Max: 0.16
Current: 0.01
During the past 13 years, the highest Debt-to-Equity Ratio of Assembly Biosciences was 0.16. The lowest was 0.01. And the median was 0.04.
ASMB's Debt-to-Equity is ranked better than 99.9% of 965
companies
in the Biotechnology industry
Industry Median: 0.16
vs ASMB: 0.01
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Assembly Biosciences Debt-to-Equity Related Terms
Assembly Biosciences Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Assembly Biosciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASMB vs CTNM, PRTA, RGNX: Debt-to-Equity Comparison
For the Biotechnology subindustry, Assembly Biosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Assembly Biosciences Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Assembly Biosciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Assembly Biosciences's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Assembly Biosciences (ASMB) has a Debt-to-Equity of 0.01 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Assembly Biosciences and its competitors. This is 75% below median its historical median of 0.04. Over the past decade, Assembly Biosciences' Debt-to-Equity has ranged from 0.01 to 0.16. According to the industry distribution chart, Assembly Biosciences ranks #1 out of 965 companies in the Biotechnology industry, placing it in the top 0.099999999999994%.
Is Assembly Biosciences' Debt-to-Equity too high?
Assembly Biosciences' current Debt-to-Equity of 0.01 is 75% below median its 10-year median of 0.04. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.16. The Biotechnology industry median Debt-to-Equity is 0.16. Assembly Biosciences' value of 0.01 is 93.8% below this industry median. Based on the distribution chart, Assembly Biosciences ranks #1 out of 965 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Assembly Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Assembly Biosciences' Debt-to-Equity compare to CTNM and PRTA?
According to the Biotechnology industry distribution chart, Assembly Biosciences ranks #1 out of 965 companies for Debt-to-Equity. This places Assembly Biosciences in the top 0% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. Assembly Biosciences' value of 0.01 is 93.8% below this benchmark. Historically, Assembly Biosciences' own Debt-to-Equity has ranged from 0.01 to 0.16 over the past decade. While the company's 10-year median is 0.04 vs. the industry median of 0.16, Assembly Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Assembly Biosciences's current Debt-to-Equity of 0.01 is 93.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Assembly Biosciences and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Assembly Biosciences's current Debt-to-Equity is 0.01, which is 75% below median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Assembly Biosciences stock overvalued right now?
Assembly Biosciences (ASMB) has a current Debt-to-Equity of 0.01. The current Debt-to-Equity is 0.01, which is 75% below median its 10-year median of 0.04 and 93.8% below the Biotechnology industry median of 0.16. Assembly Biosciences' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Assembly Biosciences (ASMB), the current Debt-to-Equity is 0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
31GF Score
Get the complete analysis for ASMB
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASMB has been successfully added to your 
